Related Experiment Videos
What can be done about acute renal failure?
1Department of Critical Care Medicine, University of Pittsburgh, School of Medicine, Pittsburgh, Pennsylvania 15261, USA. kellumja@ccm.upmc.edu
Minerva Anestesiologica
|June 3, 2004
Summary
Acute renal failure (ARF) affects 5% of hospitalized patients. While drugs have not prevented ARF, N-acetylcysteine (NAC) may reduce contrast-induced ARF, with future treatments focusing on cellular repair.
Area of Science:
- Nephrology
- Critical Care Medicine
Background:
- Acute renal failure (ARF) is a common complication in critically ill patients, affecting up to 5% of those hospitalized.
- Despite extensive research, pharmacological interventions to prevent ARF or preserve renal function in the critically ill have largely failed, with some even showing detrimental effects.
Purpose of the Study:
- To review the current understanding of ARF in critically ill patients.
- To evaluate the efficacy of existing and potential future treatments for ARF.
Main Methods:
- Review of existing literature on ARF in critically ill patients.
- Analysis of studies investigating pharmacological interventions and supportive care for ARF.
Main Results:
- Current drug therapies have not proven effective in preventing ARF onset or progression in critically ill individuals.
- Emerging evidence suggests N-acetylcysteine (NAC) may decrease ARF incidence related to radiocontrast agents.
- Advancements in renal replacement therapy (RRT) and novel drugs targeting cellular repair hold promise for improving ARF outcomes.
Conclusions:
- Pharmacological prevention of ARF in the critically ill remains a significant challenge.
- N-acetylcysteine (NAC) shows potential in specific ARF contexts, such as contrast-induced nephropathy.
- Future improvements in ARF management likely depend on enhanced RRT techniques and therapies promoting renal cellular repair.